BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis

BACKGROUND: Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a BRAF(V600E)(/K)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Frazao, Alexandra, Rethacker, Louise, Jeudy, Géraldine, Colombo, Marina, Pasmant, Eric, Avril, Marie-Françoise, Toubert, Antoine, Moins-Teisserenc, Helene, Roelens, Marie, Dalac, Sophie, Maubec, Eve, Caignard, Anne
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Basic Tumor Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482503/
https://ncbi.nlm.nih.gov/pubmed/32912923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars